H1-receptor stimulation induces hyperalgesia through activation of the phospholipase C-PKC pathway.
The supraspinal cellular events involved in H(1)-mediated hyperalgesia were investigated in a condition of acute thermal pain by means of the mouse hot-plate test. I.c.v. administration of the phospholipase C (PLC) inhibitors U-73122 and neomycin antagonized the hyperalgesia induced by the selective H(1) agonist FMPH. By contrast, U-73343, an analogue of U-73122 used as negative control, was unable to modify the reduction of the pain threshold induced by FMPH. In mice undergoing treatment with LiCl, which impairs phosphatidylinositol synthesis, or treatment with heparin, an IP(3)-receptor antagonist, the hyperalgesia induced by the H(1)-receptor agonist remained unchanged. Similarly, pretreatment with D-myo inositol did not alter the H(1)-induced hypernociceptive response. Neither i.c.v. pretreatment with TMB-8, a blocker of Ca(2+) release from intracellular stores, nor pretreatment with thapsigargin, a depletor of Ca(2+) intracellular stores, prevented the decrease of pain threshold induced by FMPH. On the other hand, i.c.v. pretreatment with the selective protein kinase C (PKC) inhibitors calphostin C and chelerytrine resulted in a dose-dependent prevention of the H(1)-receptor agonist-induced hyperalgesia. The administration of PKC activators, such as PMA and PDBu, did not produce any effect on FMPH effect. The pharmacological treatments employed did not produce any behavioral impairment of mice as revealed by the rota-rod and hole-board tests. These results indicate a role for the PLC-PKC pathway in central H(1)-induced hyperalgesia in mice. Furthermore, activation of PLC-IP(3) did not appear to play a major role in the modulation of pain perception by H(1)-receptor agonists.
Galeotti
Nicoletta
N
Department of Preclinical and Clinical Pharmacology, Viale G. Pieraccini 6, I-50139 Florence, Italy. nicoletta.galeotti@unifi.it
Malmberg-Aiello
Petra
P
Bartolini
Alessandro
A
Schunack
Walter
W
Ghelardini
Carla
C
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002118:Calcium / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005106:Exploratory Behavior / Q000187:drug effects; D006632:Histamine / Q000031:analogs & derivatives* / Q000494:pharmacology; D017442:Histamine Agonists / Q000494:pharmacology*; D006358:Hot Temperature; D006930:Hyperalgesia / Q000139:chemically induced* / Q000523:psychology; D007276:Injections, Intraventricular; D015544:Inositol 1,4,5-Trisphosphate / Q000502:physiology; D008297:Male; D051379:Mice; D010147:Pain Measurement / Q000187:drug effects; D004856:Postural Balance / Q000187:drug effects; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology*; D011930:Reaction Time / Q000187:drug effects; D011969:Receptors, Histamine H1 / Q000187:drug effects*; D015398:Signal Transduction / Q000187:drug effects*; D013268:Stimulation, Chemical; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000502:physiology*
C092716:2-(3-trifluoromethylphenyl)histamine; D004791:Enzyme Inhibitors; D017442:Histamine Agonists; D011969:Receptors, Histamine H1; D006632:Histamine; D015544:Inositol 1,4,5-Trisphosphate; D011493:Protein Kinase C; D010738:Type C Phospholipases; D002118:Calcium